LDC holds equity in several biotech companies. Two of them were founded in order to accelerate further development of promising LDC project results. Others are platform technology companies that benefit from LDC’s drug discovery expertise and professional network
Affectis Pharmaceuticals AG
Affectis is a pharmaceutical company developing a P2X7R antagonist for the treatment of neuroinflammatory diseases and additional indications. Affectis is a wholly owned subsidiary of LDC.
UGISense AG is a biotech company developing new and innovative antisense therapeutic agents in collaboration with academic and industry partners. The developments are made on the basis of a proprietary platform technology, the UgimersTM.
QLi5 Therapeutics GmbH
Dortmund-based QLi5 Therapeutics has been founded by LDC together with the Nobel laureate Prof. Dr. Robert Huber from the Max Planck Institute for Biochemistry, Martinsried, Germany, Max Planck Society, as well as Qurient, Gyeonggi-do, South Korea, with the aim of accelerating novel first-in-class proteasome inhibitors.
Dortmund-based Serengen has been founded as a joint venture between the main shareholders LDC, Taros Holding GmbH, Dortmund, Germany and Dr. Andreas Brunschweiger, a leading expert in the generation of innovative DNA-encoded compound libraries. Serengen provides access to novel DNA-encoded chemistry and a screening platform for DNA-encoded libraries.
CalTIC Therapeutics GmbH
The Dortmund-based company was founded by LDC together with University of Leeds (UK), Max Planck Society, and Prof. M. Freichel (University of Heidelberg) with the aim of developing innovative modulators for ion channels and, based on them, new drugs for the treatment of heart/metabolic diseases.